The Claim
In adults with obesity and knee osteoarthritis, treatment with once-weekly subcutaneous semaglutide at a dose of 2.4 mg for 68 weeks results in a significantly greater improvement in physical function compared to placebo, as measured by a mean increase of 12.0 points in the SF-36 physical function score versus 6.5 points with placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with obesity and knee arthritis who took a weekly semaglutide shot for over a year felt physically better than those who took a dummy shot — their ability to do everyday physical activities improved more, by about twice as much.
See the scientific wording
Treatment with once-weekly subcutaneous semaglutide at 2.4 mg for 68 weeks leads to significantly greater improvement in physical function compared to placebo in adults with obesity and knee osteoarthritis, with a mean increase of 12.0 points in SF-36 physical-function score versus 6.5 points.
What the research says
1 studyStudy: Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
The study tested the exact same drug, dose, and treatment plan as in the claim, and found that people taking semaglutide improved more in their physical function than those on placebo, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.